Highlights for November 2017
- Piramal acquires Digeplex from Shreya Lifesciences
- Morepen signs agreement with Vesale Pharma
- Eris Life to acquire Strides' India business for INR 500 crores
- Intas closing in on Mallinckrodt’s US generics business buyout
- Bayer, Loxo link in $1.55bn cancer drugs deal with $400M upfront
- Poxel has signed a deal with Sumitomo Dainippon Pharma to jointly develop its Type 2 Diabetes product Imeglimin
- Takeda taps Portal Instruments in needle-free drug delivery deal worth up to $100M
- Sanofi in $675 million deal with Principia to expand multiple sclerosis franchise
- Acerus Pharma enters hypogonadism drug licensing deal with Aspen for Brazil
- Grupo Biotoscana inks $30 million acquisition of Argentinian specialty pharmaceutical DOSA
- Zymeworks pens $50M upfront, $1B-plus biobucks Janssen bispecific pact
- Neurimmune collaborates with Ono Pharma for a novel therapeutic target for neurodegenerative diseases.
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.
Updates at Aagami:
- Aagami completes a business trip along with a UK Client with several fruitful term sheet level meetings with Top Indian companies
- Aagami team along with another client also successfully completed CEO level roadshow for strategic partnership in non-clinical/preclinical drug development strategies
- Aagami registers for Biotech Showcase 2018